Ping Zhu, H3 Biomedicine's president and CSO

Ei­sai shut­ters on­col­o­gy unit, cuts around 80 jobs

Days af­ter an­nounc­ing a re­or­ga­ni­za­tion plan to fo­cus on deep learn­ing and its “most im­por­tant project,” the Bio­gen-part­nered Alzheimer’s drug lecanemab, Ei­sai is shut­ter­ing its on­col­o­gy unit H3 Bio­med­i­cine.

The news comes af­ter H3 re­vealed in pub­lic doc­u­ments last week that it’s lay­ing off em­ploy­ees at its Cam­bridge, MA, head­quar­ters. In to­tal, 88 jobs will be af­fect­ed, a spokesper­son said. Ac­cord­ing to Mass­a­chu­setts pub­lic doc­u­ments, at least 79 will be laid off by Sept. 15.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.